Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 13/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346749 | 0.86 | ALDH1A1 (0.41) | PDK2DRD2DRD1DRD4DRD5 | |
| SCHEMBL5846694 | 0.86 | ALDH1A1 (0.41) | PDK2DRD2DRD1DRD4DRD5 | |
| SCHEMBL5846726 | 0.86 | PDK2 (0.63) | PDK2CHEK1KDM4E | |
| SCHEMBL16346844 | 0.86 | ALDH1A1 (0.41) | PDK2DRD2DRD1DRD4DRD5 | |
| SCHEMBL14427825 | 0.79 | PDK2 (0.36) | PDK2DRD1RAB9AALDH1A1KDM4E | |
| SCHEMBL13355909 | 0.78 | ALDH1A1 (0.39) | PDK2DRD2DRD1DRD4DRD5 | |
| SCHEMBL13355908 | 0.78 | ALDH1A1 (0.39) | PDK2DRD2DRD1DRD4DRD5 | |
| SCHEMBL2392834 | 0.78 | PDK2 (0.45) | PDK2ALDH1A1KDM4E | |
| SCHEMBL23598504 | 0.77 | MEN1 (0.44) | PDK2DRD1RAB9AALDH1A1KDM4E | |
| SCHEMBL30089997 | 0.77 | PDK2 (0.41) | PDK2RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7088757-B1 | Use of spiro compounds as laser dyes | SEMICONDUCTORS GMBH (DE) | 2006-08-08 | — | — | US | disclosed |
| US-6822094-B2 | AMORPHOUS SPIROBIFLUORENE COMPOUND USED IN A PHOTOVOLTIC CELL AS CHARGE TRANSPORTING MATERIAL | AVENTIS RESEARCH & TECHNOLOGIES, GMBH & CO. KG (DE) | 2004-11-23 | — | — | US | disclosed |
| EP-0935691-B1 | OPTICAL BRIGHTENING AGENT | COVION ORGANIC SEMICONDUCTORS (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-20030111107-A1 | Spiro compounds and their use | MERCK OLED MATERIALS GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-0676461-B1 | Spiro compounds and their application as electroluminescence materials | COVION ORGANIC SEMICONDUCTORS (DE) | 2002-08-14 | — | — | EP | disclosed |
| EP-1053578-B1 | USE OF SPIRO COMPOUNDS AS LASER DYES | COVION ORGANIC SEMICONDUCTORS (DE) | 2002-05-08 | — | — | EP | disclosed |
| EP-0968175-B1 | SPIRO COMPOUNDS AND THE USE THEREOF | CELANESE VENTURES GMBH (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-6187224-B1 | ORGANIC SPIRO COMPOUNDS WHICH COMPRISE A CONJUGATED SYSTEM | AXIVA GMBH (DE) | 2001-02-13 | — | — | US | disclosed |
| EP-0968175-A1 | SPIRO COMPOUNDS AND THE USE THEREOF | Aventis Research & Technologies GmbH & Co KG (DE) | 2000-01-05 | — | — | EP | disclosed |
| EP-0935691-A1 | OPTICAL BRIGHTENING AGENT | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998042655-A1 | SPIRO COMPOUNDS AND THE USE THEREOF | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998018996-A1 | OPTICAL BRIGHTENING AGENT | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-05-07 | — | — | WO | disclosed |
| EP-0676461-A2 | Spiro compounds and their application as electroluminescence materials | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030111107-A1 | Spiro compounds and their use | PKD1, PKD2, REN | PDK2 478/4885CHEK1 2164/4885STK17B 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.